AstraZeneca is currently valued at 15.1 times its 2024 estimated core price-to-earnings (P/E) ratio, compared to the sector average of 13.6 times. This reflects a robust expected compound annual growth rate (CAGR) in earnings per share (EPS) of 10.8% from 2024 to 2027, outpacing the sector's forecast of 9.4%, the Barclays note said. Looking ahead, several key catalysts are on the horizon for AstraZeneca, including developments in COVID-19 prevention, cancer treatments, and other significant drug trials. These upcoming milestones are likely to be pivotal in shaping the company's performance and, consequently, its investment appeal in the near future.